Joint Statement on the Preeminence of the U.S. Government Regulating Health Risks for Americans

• Regulators from the AMA and EMA have launched clinical trials in the Democratic Republic of the Congo and Uganda to combat the Bundibugyo Ebola virus. • The trials will test three vaccines—including mRNA, modified VSV, and ChAdOx1 adenovirus options—alongside various monoclonal antibody treatments and antiviral drugs.

• Researchers have developed a new urine test that identifies children likely to have autism by analyzing specific gut microbe profiles. • According to a study published in Molecular Psychiatry, the test correctly identified 90% of autistic children without misidentifying any neurotypical children.

• A retrospective of 2025's top infectious disease reports highlights critical events including a tuberculosis outbreak in Kansas City and a significant FDA drug approval. • The Trump administration's termination of NIH grants severely disrupted clinical trials, with infectious disease research identified as the most heavily impacted sector.

• The drug discovery technology market is projected to grow significantly, with its total size expected to surpass USD 80.27 billion by 2035. • Growth is primarily driven by the integration of genomic data and testing, which allow researchers to identify novel drug targets and analyze DNA variations.

• The Vanderbilt Report's weekly briefing for June 1–8, 2026, highlights several major medical breakthroughs, including new findings regarding GLP-1 weight-loss drugs. • Key developments include the discovery of a "striking new cancer signal" associated with GLP-1 medications and the emergence of a one-shot gene editing infusion.

• The World Health Organization (WHO) has declared the Ebola outbreak a public health emergency, prompting employers to review operational and workforce safety considerations. • While the risk to the general population in Europe remains very low, individuals returning from affected areas are advised to seek medical care if symptoms appear within 21 days.

• A wave of high-profile resignations and firings has created a leadership vacuum at the top of the CDC and FDA. • These departures suggest the Trump administration may be pivoting away from specific goals of the "Make America Healthy Again" (MAHA) movement.

• A phase II trial published in Nature Medicine found that combining the drug apitegromab with tirzepatide (Zepbound) effectively preserves lean muscle mass, potentially mitigating the muscle loss known as "Ozempic butt." • Massachusetts General Hospital has established a novel vascular clinic specifically designed to provide critical care to homeless individuals to prevent amputations caused by peripheral artery disease.

• The British Palace has issued an official statement announcing that a member of the Royal Family will undergo major surgery. • The decision to proceed with the operation follows a period where the royal's health reportedly worsened.

• MarketBeat’s stock screener tool identified Eli Lilly and Company, Pfizer, and AbbVie as the top three pharmaceutical stocks to watch on June 8th. • These companies operate within the pharmaceutical sector, focusing on the development, manufacturing, and sale of prescription drugs, vaccines, and over-the-counter medicines.

• The COVID-19 pandemic in early 2020 exposed critical vulnerabilities in global health systems and their inability to manage large-scale infectious disease outbreaks. • The crisis highlighted several converging risk factors, including agricultural intensification, increased human-animal contact, rapid urbanization, and shifting climatic patterns.